BACKGROUND: We investigated the incidence of eukaryotic translation initiation factor 3 subunit H (EIF3H) and MYC amplification in non-small cell lung cancer (NSCLC) patients, and whether MYC/EIF3H increased gene copy number affected response to Epidermal Growth Factor Receptor tyrosine kinase inhibitors. METHODS: Metastatic NSCLC patients (n = 54) treated with gefitinib were analyzed for the genomic content of EIF3H and MYC genes by fluorescence in situ hybridization (FISH) using a custom-designed 3-color DNA probe set. RESULT: Amplification of EIF3H (ratio EIF3H/CEP8 >2), was observed in 10 cases (18.5%), and MYC was coamplified in all. MYC amplification without coamplification of EIF3H was observed in 2 cases (3.7%). Receiver operating characteristic analysis was conducted to identify the cutoff for MYC and EIF3H copy number best discriminating sensitive and resistant populations. MYC FISH positive patients (MYC+, mean > or =2.8) had a significantly higher response rate (p = 0.003), longer time to progression (p = 0.01) and overall survival (OS: p = 0.02) than MYC- (mean <2.8). Similarly, EIF3H FISH positive patients (EIF3H+, mean > or =2.75) had a significantly higher response rate (p = 0.002), longer time to progression (p = 0.01) and OS (p = 0.01) than EIF3H- (mean <2.75). CONCLUSION: Our results indicate that MYC and EIF3H are frequently coamplified in NSCLC and that a high copy number correlates with increased epidermal growth factor receptor tyrosine kinase inhibitors sensitivity.
BACKGROUND: We investigated the incidence of eukaryotic translation initiation factor 3 subunit H (EIF3H) and MYC amplification in non-small cell lung cancer (NSCLC) patients, and whether MYC/EIF3H increased gene copy number affected response to Epidermal Growth Factor Receptor tyrosine kinase inhibitors. METHODS: Metastatic NSCLCpatients (n = 54) treated with gefitinib were analyzed for the genomic content of EIF3H and MYC genes by fluorescence in situ hybridization (FISH) using a custom-designed 3-color DNA probe set. RESULT: Amplification of EIF3H (ratio EIF3H/CEP8 >2), was observed in 10 cases (18.5%), and MYC was coamplified in all. MYC amplification without coamplification of EIF3H was observed in 2 cases (3.7%). Receiver operating characteristic analysis was conducted to identify the cutoff for MYC and EIF3H copy number best discriminating sensitive and resistant populations. MYC FISH positive patients (MYC+, mean > or =2.8) had a significantly higher response rate (p = 0.003), longer time to progression (p = 0.01) and overall survival (OS: p = 0.02) than MYC- (mean <2.8). Similarly, EIF3H FISH positive patients (EIF3H+, mean > or =2.75) had a significantly higher response rate (p = 0.002), longer time to progression (p = 0.01) and OS (p = 0.01) than EIF3H- (mean <2.75). CONCLUSION: Our results indicate that MYC and EIF3H are frequently coamplified in NSCLC and that a high copy number correlates with increased epidermal growth factor receptor tyrosine kinase inhibitors sensitivity.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: H A Coller; C Grandori; P Tamayo; T Colbert; E S Lander; R N Eisenman; T R Golub Journal: Proc Natl Acad Sci U S A Date: 2000-03-28 Impact factor: 11.205
Authors: G T Chang; M Steenbeek; E Schippers; L J Blok; W M van Weerden; D C van Alewijk; B H Eussen; G J van Steenbrugge; A O Brinkmann Journal: J Natl Cancer Inst Date: 2000-09-06 Impact factor: 13.506
Authors: W W Lockwood; R Chari; B P Coe; L Girard; C Macaulay; S Lam; A F Gazdar; J D Minna; W L Lam Journal: Oncogene Date: 2008-04-07 Impact factor: 9.867
Authors: Richard Marcotte; Kevin R Brown; Fernando Suarez; Azin Sayad; Konstantina Karamboulas; Paul M Krzyzanowski; Fabrice Sircoulomb; Mauricio Medrano; Yaroslav Fedyshyn; Judice L Y Koh; Dewald van Dyk; Bodhana Fedyshyn; Marianna Luhova; Glauber C Brito; Franco J Vizeacoumar; Frederick S Vizeacoumar; Alessandro Datti; Dahlia Kasimer; Alla Buzina; Patricia Mero; Christine Misquitta; Josee Normand; Maliha Haider; Troy Ketela; Jeffrey L Wrana; Robert Rottapel; Benjamin G Neel; Jason Moffat Journal: Cancer Discov Date: 2011-12-29 Impact factor: 39.397
Authors: Masatoshi Kakihana; Tatsuo Ohira; Daniel Chan; Robin B Webster; Harubumi Kato; Harry A Drabkin; Robert M Gemmill Journal: J Thorac Oncol Date: 2009-12 Impact factor: 15.609
Authors: Xiaoping Yang; Elizabeth Kessler; Lih-Jen Su; Andrew Thorburn; Arthur E Frankel; Yuan Li; Francisco G La Rosa; Jingping Shen; Chuan-Yuan Li; Marileila Varella-Garcia; L Michael Glodé; Thomas W Flaig Journal: Clin Cancer Res Date: 2012-11-21 Impact factor: 12.531
Authors: Hong Wang; Yuanbin Ru; Marta Sanchez-Carbayo; Xuejiao Wang; Jeffrey S Kieft; Dan Theodorescu Journal: Clin Cancer Res Date: 2013-04-10 Impact factor: 12.531
Authors: Marie-Eve Beaulieu; Toni Jauset; Daniel Massó-Vallés; Sandra Martínez-Martín; Peter Rahl; Loïka Maltais; Mariano F Zacarias-Fluck; Sílvia Casacuberta-Serra; Erika Serrano Del Pozo; Christopher Fiore; Laia Foradada; Virginia Castillo Cano; Meritxell Sánchez-Hervás; Matthew Guenther; Eduardo Romero Sanz; Marta Oteo; Cynthia Tremblay; Génesis Martín; Danny Letourneau; Martin Montagne; Miguel Ángel Morcillo Alonso; Jonathan R Whitfield; Pierre Lavigne; Laura Soucek Journal: Sci Transl Med Date: 2019-03-20 Impact factor: 17.956